REG - Venture Life Group - Sale of Non-Core Products

Venture LifeAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI7351Ka&default-theme=true

RNS Number : 7351K  Venture Life Group PLC  09 December 2025

THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS
STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS
PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED
TO BE IN THE PUBLIC DOMAIN

9 December 2025

VENTURE LIFE GROUP PLC

("Venture Life" or the "Company")

Sale of non-core products for up to £4.5m in cash on a cash free, debt free
basis

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces
that, further to the disclosure made in the FY24 Final Results announcement,
it has completed the sale of its Ultradex and Dentyl brands, including 100 per
cent. of the issued share capital of Periproducts Limited, (the "Oral Care
Assets") for an enterprise value of up to £4.5 million (the "Sale") on a cash
free, debt free basis to Covestus Holdings Ltd.

 

The consideration for the Sale is payable in cash, with £3.75m paid to the
Company on completion that is subject to customary working capital
adjustments. A further amount of up to £0.75m will be payable in cash
contingent upon the Oral Care Assets achieving expected trading results for
the 12 months post completion. As part of the Sale, the Oral Care Assets and
the Company will enter into a transitional services agreement until end of
February 2026 to ensure a smooth transition.

 

The net proceeds of the Sale will further bolster Venture Life and its
subsidiaries (the "Group") with additional financial resources for its
acquisition strategy.

 

Strategic rationale

 

The Oral Care Assets do not form part of the future strategic direction of the
Company and so the decision has been taken to divest of these assets. Venture
Life is now focusing its efforts and resources on the Group's higher margin,
higher growth core brands in its key target categories, to promote and support
the Proactive Healthy Longevity of consumers. Its current core brands include
Balance Activ, Health & Her/Him, Lift and Earol,  (collectively the
"Power Brands"), and the funds raised through the Sale will be utilised
alongside the existing available funds of the business to drive innovation and
growth in the Power Brands, as well as to acquire interesting complementary
brands with a pathway to profitable growth.

 

The Sale also presents the opportunity for the Board to further streamline the
Company's operations and product portfolio through the disposal of non-core
assets and to focus additional resources into the commercialisation, growth
and development of the Power Brands. At the same time, it enables the Company
to realise cash at a multiple of c.11x FY24 adjusted EBITDA, which it can
redeploy both into the organic growth of its existing Power Brands and the
acquisition of carefully selected, margin accretive, high growth assets within
the Group's core categories of interest.

 

For the financial year ended 31 December 2024 the audited results of the Oral
Care Assets generated revenues of £4.3 million and adjusted EBITDA of £0.4
million. As at 30 November 2025, the Oral Care Assets had a net carrying value
of £4.5 million.

 

 

Jerry Randall, Chief Executive Officer, commented: "I am pleased that we have
been able to divest of these non-core assets to a new owner that will continue
to develop them. As we have indicated before these assets no longer form part
of our strategic vision for Venture Life, so the divestment allows us to
recycle the funds raised into our core focus categories and brands working out
our 5-pillar strategic growth plan.

 

I am delighted with the post divestment progress since we disposed of our CDMO
businesses earlier this year, and the collaboration with the Healthea Group
(the purchasers of our CDMO businesses) where we are growing and strengthening
the ongoing relationship for our mutual profitable growth. Aswell as
generating significant funds for us to drive the growth of Venture Life, the
divestment to the Healthea Group has also bought significant operational
benefits including accelerated innovation opportunities and strengthened
quality of supply. These two divestments have significantly simplified the
Group and in conjunction with our new Microsoft D365 ERP system, which is now
going live, we have a much more streamlined, agile and scalable business."

 

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys / George Lawson (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, the Health
and Her product range supporting the hormonal lifecycle, the UltraDEX and
Dentyl oral care product ranges. The products, which are typically recommended
by pharmacists or healthcare practitioners, are available primarily through
pharmacies and grocery multiples and are sold in over 90 countries worldwide.
In the UK and The Netherlands these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISFFFVFFFLTIIE



            Copyright 2019 Regulatory News Service, all rights reserved